Article | February 11, 2016

Big Data Is Key To Risk-Based Study Startup In Clinical Trials

Big Data Is Key To Risk-Based Study Startup In Clinical Trials

By Craig Morgan NZCS, MBA (Hons), PMP, goBalto, Inc.

The process of initiating clinical trials is cumbersome, challenging and fraught with delays – it has the greatest impact on patient recruitment, trial duration and its associated costs, unfortunately, it is also the worst performing stage of any clinical trial. Study startup is the most resource- and labor-intensive period in a study’s life cycle after data cleaning and database lock activities. Any increase of duration or responsibilities during startup has an increased logistical and financial impact. According to the CenterWatch Survey of Investigative Sites in the U.S., nearly 70 percent of all trials experience enrollment delays (1), while nearly half complete later than originally planned (2) and one-fifth of sites never recruit a single subject (3).

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: